Has Nausheen Ahmed, MD received payments from drug or device companies?

Yes. Drug and device makers reported $60,768 in general payments to Nausheen Ahmed, MD across 82 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Nausheen Ahmed, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Nausheen Ahmed, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Nausheen Ahmed, MD

Hematology · Westwood, KSNPI 1750519856

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $43,910 of the $60,768 with a category attached, or 72.3%. 21 manufacturers reported payments, led by Gilead at 44.2% of the total. 2025 is the largest year on record at $36,120, more than ten times the $559 reported in 2019.

$60,768in general payments, 2019–2025

Across 82 payments — averaging $741.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Gilead$27K
ADC Therapeutics America, Inc.$12K
E.r. Squibb & Sons, L.L.C.$10K
AbbVie$3K
AstraZeneca$3K
Legend Biotech USA Inc.$2K
plus $4K from 15 others

$974,128in research payments, 2019–2025

Across 145 payments — averaging $6718.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Gilead$781K
Genmab U.S., Inc.$104K
Pfizer$63K
Bristol Myers Squibb$26K
E.r. Squibb & Sons, L.L.C.$948

What the payments were for

Consulting fees$43,91072%
Speaking & faculty fees$10,50017%
Travel & lodging$2,3274%
Food & beverage$4,0047%
Education$270%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Gilead	27	$26,871
ADC Therapeutics America, Inc.	12	$11,556
E.r. Squibb & Sons, L.L.C.	9	$9,529
AbbVie	6	$3,072
AstraZeneca	1	$2,870
Legend Biotech USA Inc.	1	$2,463
Invivyd Inc	1	$2,100
Genentech USA, Inc.	5	$337
Johnson & Johnson	2	$268
Genentech, Inc.	3	$249
National Marrow Donor Program	1	$215
Bristol Myers Squibb	2	$197
Sanofi	3	$195
Syndax Pharmaceuticals, Inc.	1	$146
Janssen Scientific Affairs, LLC	2	$139
Novartis	1	$118
Genmab U.S., Inc.	1	$111
Merck	1	$100
Lilly USA, LLC	1	$100
Incyte Corporation	1	$91
Sanofi-aventis U.S. LLC	1	$42

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Yescarta$23,959
ZYNLONTA$11,205
EPKINLY$3,011
CALQUENCE$2,870
CARVYKTI$2,608
PEMGARDA$2,100
TECVAYLI$122
TALVEY$122
KYMRIAH$118
Pomalyst$116
MOZOBIL$116
KEYTRUDA$100
VERZENIO$100

How this compares

Too few hematology providers in Kansasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024

$133,699

Medicare patients

249

Services billed

1,300

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
ShingrixVaricella-Zoster Ge/As01b/Pf	33	$5,920
PentacelDipht,pert(A),tet-Polio/Hib/Pf	48	$4,993
Menveo A-C-Y-W-135-DipMening Vac A,c,y,w-135 Dip/Pf	30	$4,801
ArexvyRsvpref3 Antigen/As01e/Pf	17	$4,354
Acyclovir	63	$885
Dapsone	22	$714
Pantoprazole Sodium	13	$262
Prochlorperazine Maleate	14	$237
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim	54	$183
Levofloxacin	12	$136
Levothyroxine Sodium	15	$132
Prednisone	15	$83
Sumatriptan Succinate	11	$56
Amoxicillin	12	$11

Paid to pharmacies, not to this prescriber.

Other hematology in Westwood

Aung TunWestwood$17K
Forat LutfiWestwood$12K
Alma HabibWestwood$369
Konstantine HalkidisKansas City$16K
Barry SkikneKansas City$4K
Robert KribsKansas City$824
Edwin PetrikTopeka$779

See the full list for Kansas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →